Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
Chugai Pharmaceutical Co., 10/01/09

Roche announced that it has submitted a filing to the European health authorities to extend the indication of RoACTEMRA to inhibit the progression of joint damage and to improve physical function in patients with rheumatoid arthritis. Joint damage in RA often begins early in the disease and can lead to permanent disability, so inhibiting this structural damage to patients' joints is a critical measure of effectiveness of an RA treatment.

Today in Research & Development...keeping you current

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

CCHIT Appoints Officers
HealthDataManagement, 12/18/09

 See all of Research & Development

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address